Batavia Biosciences Partners with VBC and MEVAC to Advance Localized Vaccine Manufacturing in Egypt

Batavia Biosciences, a Netherlands-based CDMO, agreed to collaborate with Vaccine Biotechnology City (VBC) and MEVAC, two organizations in Egypt. The partnership aims to enhance local vaccine manufacturing capabilities, focusing initially on measles, rubella, and rotavirus. Batavia will license proprietary processes, analytical methods, and production systems to VBC and MEVAC to enable them to produce vaccines locally and meet international standards. The collaboration builds on a previously signed license agreement for measles and rubella vaccines, with negotiations for rotavirus vaccines currently underway.